Global venture capital firm New Enterprise Associates announced the promotions of three members of its investing team:
– Frank Torti, M.D., to Partner;
– Rick Yang to Partner; and
– Aaron Jacobson to Principal.
Frank Torti, who joined NEA in 2007, has focused on investments across the healthcare spectrum, particularly in biopharma and medical devices. He has worked closely with Dermira and is a director of NeoTract, Galera Therapeutics, and Cerecor. In addition, Dr. Torti represents NEA’s healthcare team on the firm’s China Investment Committee and was involved in investments in China-based CITIC Pharmaceuticals (acquired by Shanghai Pharmaceuticals) and Novast Pharmaceuticals. He has also focused on NEA’s public healthcare investment practice, including investments in Alimera Sciences, Cadence Pharmaceuticals (acquired by Mallinckrodt plc), Peplin (acquired by LEO Pharma), Rigel, and Solta Medical (acquired by Valeant).
Rick Yang, who joined NEA in 2007, is focused on information and financial technology investments. He also co-manages NEA’s seed practice. Mr. Yang is currently on the board of mNectar and TabbedOut, and he works closely with Euclid, Fyusion, GoEuro, Olio Devices, Plaid, Soraa, and Stride Health. He was historically involved with Braintree (acquired by PayPal), Gaikai (acquired by Sony), and Pure Energies (acquired by NRG).
Aaron Jacobson, who joined NEA in 2011, is focused on information and energy technology, with associated investments including Bloom Energy, Box, Conviva, Coursera, IIX, Gainspeed, Kumu, Lattice, Mimosa, Move Guides, NGINX, Philo, and Stormpath.